These agonists activate GLP-1R, enhancing insulin secretion, inhibiting glucagon release, delaying gastric emptying, and suppressing appetite through central mechanisms, making them valuable therapeutic agents for metabolic disorder [102]. Here, GLP1R is linked to Other metabolic disease.